Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL June 13, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology May 30, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication May 23, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala May 22, 2019 • 4:19 PM EDT
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology May 21, 2019 • 4:15 PM EDT
Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights May 13, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA May 8, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) April 23, 2019 • 1:51 PM EDT
